EMA Refused: Omblastys (iodine (131I) omburtamab) — Y-Mabs Therapeutics A/S

View source ↗

Summary

EMA refused the Omblastys application (iodine-131 omburtamab) for neuroblastoma, leading to no approval at this time.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Omblastys (iodine-131 omburtamab)

Snippet

Status: Refused. Therapeutic area: Neuroblastoma. MAH: Y-Mabs Therapeutics A/S. Decision date: 15/12/2022. Orphan medicine